FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551002076> ?p ?o ?g. }

• W2551002076 abstract "Abstract Abstract 765 BCR-ABL1 tyrosine kinase inhibitors (TKI) are widely used for the treatment of patients with Ph+ ALL and CML. To elucidate mechanisms of TKI-resistance in Ph+ ALL, we studied gene expression changes of a set of 11 primary cases of Ph+ ALL in response to TKI-treatment (16 hours; 2 μmol/l Imatinib). Sorting genes based on the ratio of gene expression values in the presence vs the absence of TKI-treatment, the BCL6 gene consistently ranked #1 in this analysis. As confirmed by quantitative RT-PCR and Western blotting, BCL6 is upregulated by 60- to 90-fold in response to TKI-treatment of Ph+ ALL cells. The BCL6 transcription factor functions as a protooncogene in germinal center (GC)-derived B cell lymphomas. We focused our analysis on BCL6, because it functions a transcriptional repressor of p53 and other cell cycle check point regulators and thereby protects GC-derived B cell lymphoma cells from apoptosis. Of note, BCL6 protein levels in TKI-treated Ph+ ALL cells were as high as in GC-derived B cell lymphoma. We hypothesize that dramatic upregulation of the BCL6 gene in response to TKI-treatment represents a defense mechanism of Ph+ ALL to evade cell death induced by activation of p53 and cell cycle checkpoint regulators. We tested the role of BCL6 in Ph+ ALL in a genetic loss-of-function experiment: To this end, B cell precursors from bone marrow of BCL6+/+ and BCL6−/− mice were transformed with BCR-ABL1. Upon treatment with 1 mmol/l Imatinib for three days, viability of BCL6−/− BCR-ABL1 ALL cells (0.4% ± 0.2%) was lower by two log orders compared to BCL6+/+ leukemia cells (46.0% ± 8.2%; p=0.001). Consistent with our hypothesis that p53 and other cell cycle checkpoint regulators are transcriptional targets of BCL6 in Ph+ ALL, we observed in a comprehensive gene expression analysis that mRNA levels of p53, p21, Arf and p27 were significantly higher in BCL6−/− compared to BCL6+/+ and BCR-ABL1 ALL cells (confirmed by quantitative RT-PCR). To identify target genes of the BCL6 transcriptional repressor, we performed a ChIP-chip analysis for BCL6 both in Ph+ ALL and GC-derived B cell lymphoma. Among the 1,235 target genes of BCL6 in Ph+ ALL, 736 were shared targets with GC-derived B cell lymphoma and 499 were exclusive for Ph+ ALL. These findings suggest that the function of BCL6 in Ph+ ALL does not replicate all aspects of its function in GC-B cell lymphoma. Single locus ChIP analysis confirmed strong recruitment of BCL6 to the promoter regions of the p53, p21 (CDKN1A), Arf (CDKN2A) and p27 (CDKN1B) genes in human Ph+ ALL cells after TKI-treatment. In a genetic loss-of-function experiment, we tested whether transcriptional suppression of p53, p21, Arf and p27 represents a major function of BCL6-upregulation in response to TKI-treatment in Ph+ ALL. To this end, we measured sensitivity of wildtype and Arf−/−, p53−/−, p21−/− and p27−/− BCR-ABL1 ALL cells to either Imatinib alone or to a combination of Imatinib and a novel BCL6 peptide inhibitor (RI-BPI). TKI-treatment alone had approximately the same effect in wildtype BCR-ABL1 ALL cells compared to Arf−/−, p53−/−, p21−/− and p27−/− counterparts. However, when TKI-treatment was combined with BCL6 inhibition (5 μmol/l RI-BPI), the viability of Arf−/−, p53−/−, p21−/− and to lesser degree, p27−/−BCR-ABL1 ALL cells was significantly higher than survival of the respective wildtype control leukemia. These findings confirm that transcriptional suppression of Arf, p53 and p21 (to lesser extent p27) represents an important characteristic of BCL6-mediated drug-resistance in response to TKI-treatment. We next tested the potential therapeutic usefulness of concomitant TKI-treatment and BCL6 peptide inhibition: To this end, 2 × 106 BCR-ABL1 ALL cells were luciferase-labeled and injected into sublethally irradiated NOD/SCID mice. Mice were treated six times between days 7 and 21 after leukemia cell injection with either the BCR-ABL1 kinase inhibitor Nilotinib (75 mg/kg) alone or a combination of Nilotinib and RI-BPI (20 mg/kg). Addition of RI-BPI resulted in significantly prolonged median survival (29 days) compared to Nilotinib alone (22 days; 12 mice per group; p=0.004). We conclude that BCL6-mediated transcriptional repression of p53 and other cell cycle checkpoint regulators represents a novel and critical mechanism of drug-resistance in Ph+ ALL. Combination of TKI-treatment with BCL6 peptide inhibition represents a new promising approach to target drug-resistance in Ph+ ALL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2551002076 created "2016-11-30" @default.
• W2551002076 creator A5017078665 @default.
• W2551002076 creator A5019770989 @default.
• W2551002076 creator A5044113220 @default.
• W2551002076 creator A5056366117 @default.
• W2551002076 creator A5059389744 @default.
• W2551002076 creator A5059800716 @default.
• W2551002076 creator A5060882282 @default.
• W2551002076 creator A5064523130 @default.
• W2551002076 creator A5064564304 @default.
• W2551002076 creator A5074664283 @default.
• W2551002076 creator A5081096741 @default.
• W2551002076 date "2009-11-20" @default.
• W2551002076 modified "2023-10-01" @default.
• W2551002076 title "BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia." @default.
• W2551002076 doi "https://doi.org/10.1182/blood.v114.22.765.765" @default.
• W2551002076 hasPublicationYear "2009" @default.
• W2551002076 type Work @default.
• W2551002076 sameAs 2551002076 @default.
• W2551002076 citedByCount "0" @default.
• W2551002076 crossrefType "journal-article" @default.
• W2551002076 hasAuthorship W2551002076A5017078665 @default.
• W2551002076 hasAuthorship W2551002076A5019770989 @default.
• W2551002076 hasAuthorship W2551002076A5044113220 @default.
• W2551002076 hasAuthorship W2551002076A5056366117 @default.
• W2551002076 hasAuthorship W2551002076A5059389744 @default.
• W2551002076 hasAuthorship W2551002076A5059800716 @default.
• W2551002076 hasAuthorship W2551002076A5060882282 @default.
• W2551002076 hasAuthorship W2551002076A5064523130 @default.
• W2551002076 hasAuthorship W2551002076A5064564304 @default.
• W2551002076 hasAuthorship W2551002076A5074664283 @default.
• W2551002076 hasAuthorship W2551002076A5081096741 @default.
• W2551002076 hasConcept C104317684 @default.
• W2551002076 hasConcept C127561419 @default.
• W2551002076 hasConcept C153911025 @default.
• W2551002076 hasConcept C159654299 @default.
• W2551002076 hasConcept C185592680 @default.
• W2551002076 hasConcept C190283241 @default.
• W2551002076 hasConcept C203014093 @default.
• W2551002076 hasConcept C2777537477 @default.
• W2551002076 hasConcept C2777583451 @default.
• W2551002076 hasConcept C2778453870 @default.
• W2551002076 hasConcept C2778729363 @default.
• W2551002076 hasConcept C29537977 @default.
• W2551002076 hasConcept C3019892230 @default.
• W2551002076 hasConcept C502942594 @default.
• W2551002076 hasConcept C54355233 @default.
• W2551002076 hasConcept C86803240 @default.
• W2551002076 hasConcept C96926380 @default.
• W2551002076 hasConceptScore W2551002076C104317684 @default.
• W2551002076 hasConceptScore W2551002076C127561419 @default.
• W2551002076 hasConceptScore W2551002076C153911025 @default.
• W2551002076 hasConceptScore W2551002076C159654299 @default.
• W2551002076 hasConceptScore W2551002076C185592680 @default.
• W2551002076 hasConceptScore W2551002076C190283241 @default.
• W2551002076 hasConceptScore W2551002076C203014093 @default.
• W2551002076 hasConceptScore W2551002076C2777537477 @default.
• W2551002076 hasConceptScore W2551002076C2777583451 @default.
• W2551002076 hasConceptScore W2551002076C2778453870 @default.
• W2551002076 hasConceptScore W2551002076C2778729363 @default.
• W2551002076 hasConceptScore W2551002076C29537977 @default.
• W2551002076 hasConceptScore W2551002076C3019892230 @default.
• W2551002076 hasConceptScore W2551002076C502942594 @default.
• W2551002076 hasConceptScore W2551002076C54355233 @default.
• W2551002076 hasConceptScore W2551002076C86803240 @default.
• W2551002076 hasConceptScore W2551002076C96926380 @default.
• W2551002076 hasLocation W25510020761 @default.
• W2551002076 hasOpenAccess W2551002076 @default.
• W2551002076 hasPrimaryLocation W25510020761 @default.
• W2551002076 hasRelatedWork W1548362784 @default.
• W2551002076 hasRelatedWork W2097072837 @default.
• W2551002076 hasRelatedWork W2157637767 @default.
• W2551002076 hasRelatedWork W2241114767 @default.
• W2551002076 hasRelatedWork W2551572632 @default.
• W2551002076 hasRelatedWork W2552244767 @default.
• W2551002076 hasRelatedWork W2555742511 @default.
• W2551002076 hasRelatedWork W2562574768 @default.
• W2551002076 hasRelatedWork W2573802242 @default.
• W2551002076 hasRelatedWork W2575767755 @default.
• W2551002076 hasRelatedWork W2578866250 @default.
• W2551002076 hasRelatedWork W2582241124 @default.
• W2551002076 hasRelatedWork W2582501737 @default.
• W2551002076 hasRelatedWork W2605098055 @default.
• W2551002076 hasRelatedWork W2606156290 @default.
• W2551002076 hasRelatedWork W2803209898 @default.
• W2551002076 hasRelatedWork W2968069642 @default.
• W2551002076 hasRelatedWork W2985729086 @default.
• W2551002076 hasRelatedWork W2986341305 @default.
• W2551002076 hasRelatedWork W2567958905 @default.
• W2551002076 isParatext "false" @default.
• W2551002076 isRetracted "false" @default.
• W2551002076 magId "2551002076" @default.
• W2551002076 workType "article" @default.